https://www.selleckchem.com/products/PP242.html
ing precaution when the two strategies are combined. Immunotherapy agents offer novel treatment options in advanced cancers. However, their use is limited in developing countries lacking unifying guidelines and can be followed by a financial burden. In this study, we aimed to provide an overview regarding the use of immunotherapy and the overall response to treatment in patients with metastatic disease in relation to cost-effectiveness. This was a retrospective study involving adult metastatic cancer patients, treated with programmed cell